glsi-100
glsi-100: sourced relationships with 1 company · 1 clinical trial tracked.
glsi-100 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could glsi-100 → GLSI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | Phase 3 |
Clinical Trial Registry Records (1)
A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Primary endpoint: Invasive Breast Cancer-free Survival (IBCFS)
Frequently asked questions
Which companies have sourced relationships with glsi-100?
glsi-100 has dated SEC/FDA relationship records for Greenwich LifeSciences, Inc..
How many clinical trials involve glsi-100?
BioSniper tracks 1 clinical trial involving glsi-100.